Bacopa monnieri

The best-evidenced traditional adaptogen for memory consolidation and delayed recall — A-tier replicated RCTs in healthy young adults at 300 mg/day standardized extract. Effect size is small-to-medium and takes 8-12 weeks of daily dosing to emerge — there is no acute cognitive lift. Mild sedation in 5-15% of users is the principal concern for a daily-sparring MMA athlete. For Dylan: OPTIONAL-ADD as a 12-week trial, but only if he commits to the full build-up window and is willing to drop it if PM training feels heavy.

Bacopa's actives are bacoside A + B — dammarane-type triterpenoid saponins extracted from the leaves. The clinical effect runs through five overlapping pathways:

1. Cholinergic modulation. Bacosides increase synaptic ACh availability through a combination of mild AChE inhibition (modest, far weaker than donepezil/galantamine) and increased ChAT activity in hippocampus + cortex (animal data). The net effect is enhanced cholinergic tone in memory-relevant circuits without the cholinergic-excess profile of pharmaceutical AChE inhibitors.
2. BDNF + neurotrophic upregulation. Chronic dosing (≥6 weeks) increases hippocampal BDNF and CREB phosphorylation in rodent models. This is the mechanism most plausibly tied to the delayed recall signal in human RCTs — memory consolidation requires synaptic strengthening, which requires BDNF-driven protein synthesis.
3. Dendritic remodeling. Bacosides increase dendritic branching + spine density in hippocampal CA3 pyramidal neurons (replicated in rats at 40-80 mg/kg × 4-6 weeks). This is a slow structural change — the kinetic explanation for why Bacopa needs weeks-to-months to "feel different."
4. Antioxidant + heat-shock protein induction. Bacopa upregulates SOD, catalase, glutathione peroxidase, and HSP70 in brain tissue. This is the "neuroprotective" axis — relevant for chronic oxidative load (aging, ischemic stress, repetitive impact).
5. 5-HT1A agonism + anxiolysis. Bacosides bind 5-HT1A presynaptically and postsynaptically; the result is a calming/anxiolytic profile similar in flavor (but weaker) to buspirone. This is the mechanism behind both the anxiolytic effect and the sedation side effect — same axis, different dose-responses by individual.

On AChE inhibition magnitude: widely cited but quantitatively modest. Bacopa is not a clinically meaningful AChE inhibitor in the donepezil sense; the cholinergic effect is dominated by ChAT upregulation + downstream BDNF effects. Don't stack with prescription AChE inhibitors expecting only additive benefit — see drug interactions.

On the "adaptogen" framing. Bacopa fits the Russian-adaptogen definition (non-specific resistance to stressors) better than rhodiola for cognitive stress specifically, and worse for physical stress. The HPA-axis modulation is real but secondary to the cholinergic + neurotrophic effects.